One-pot synthesis of acyclic nucleosides from carbohydrate derivatives, by combination of tandem and sequential reactions

Journal of Organic Chemistry

Volumn 72, Issue 25, 2007, Pages 9523-9532

  Boto, Alicia ^a   Hernández, Dácil ^a   Hernández, Rosendo ^a   Álvarez, Eleuterio ^b  

^a INSTITUTO DE PRODUCTOS NATURALES Y AGROBIOLOGÍA   (Spain)

^b INSTITUTO DE INVESTIGACIONES QUÍMICAS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

FUNCTIONAL GROUPS; HYDROXYLATION; SUGARS; SYNTHESIS (CHEMICAL);

ANTIVIRAL COMPOUNDS; CARBOHYDRATE DERIVATIVES; NUCLEOSIDES;

DERIVATIVES;

ACRYLIC ACID DERIVATIVE; ANTIVIRUS AGENT; CARBOHYDRATE DERIVATIVE; HYDROXYL GROUP; NUCLEOSIDE DERIVATIVE; SUGAR;

ARTICLE; CHEMICAL REACTION KINETICS; DRUG STRUCTURE; DRUG SYNTHESIS; FRAGMENTATION REACTION; ONE POT SYNTHESIS; OXIDATION; PHOSPHORYLATION; RADICAL REACTION; STRUCTURE ANALYSIS;

CARBOHYDRATES; MOLECULAR STRUCTURE; NUCLEOSIDES; STEREOISOMERISM;

EID: 36849059218     PISSN: 00223263     EISSN: None     Source Type: Journal    
DOI: 10.1021/jo701608p     Document Type: Article

References (79)

1. (a) For interesting introductions to the subject, see: de Clercq, E. Antiviral Res. 2005, 67, 56-75.
2. (b) Holý, A. Synthesis and biological activity of isopolar acyclic nucleotide analogs. In Recent Advances in Nucleosides: Chemistry and Chemotherapy; Chu, C. K., Ed.; Elsevier: New York, 2002; pp 167-238.
3. (c) For other reviews, see: de Clercq, E. Biochem. Pharmacol. 2007, 73, 911-922.
4. (d) de Clercq, E. Antiviral Res. 2007, 75, 1-13.
5. (e) Lee, W. A.; Martin, J. C. Antiviral Res. 2006, 71, 254-259.
6. (f) Holý, A. Antiviral Res. 2006, 71, 248-253.
7. (g) Meier, C. Eur. J. Org. Chem. 2006, 1081-1102.
8. (h) Meier, C.; Balzarini, J. Antiviral Res. 2006, 71, 282-292.
9. (i) Griffiths, P. D. Antiviral Res. 2006, 71, 192-200.
10. (j) Biron, K. K. Antiviral Res. 2006, 71, 154-163.
11. (k) Golankiewicz, B.; Ostrowski, T. Antiviral Res. 2006, 71, 134-140.
12. (l) de Clercq, E. Rev. Med. Virol. 2004, 14, 289-300.
13. (m) de Clercq, E. Trends Pharmacol. Sci. 2002, 23, 456-458.
14. (n) Fung, H. B.; Stone, E. A.; Piacenti, F. J. Clin. Ther. 2002, 24, 1515-1548.
15. (o) Gao, H.; Mitra, A. K. Synthesis 2000, 329-351.
16. (a) For a review, see: Abdulkarim, B.; Bourhis, J. Lancet Oncol. 2001, 2, 622-630.
17. (b) For some articles on the subject, see: Tristram, A.; Fiander, A. Gynecol. Oncol. 2005, 99, 652-655.
18. (c) Votruba, I.; Pomeisl, K.; Tloust'ová, E.; Holý, A.; Otová, B. Biochem. Pharmacol. 2005, 69, 1517-1521.
19. (d) He, L.; Liu, Y.; Zhang, W.; Li, M.; Chen, Q. Tetrahedron 2005, 65, 8505-8511.
20. (e) Hâjek, M.; Matulová, N.; Votruba, I.; Holý, A.; Tloustová, E. Biochem. Pharmacol. 2005, 70, 894-900.
21. (f) Bobková, K.; Otová, B.; Marinov, I.; Mandys, V.; Panczak, A.; Votruba, I.; Holý, A. Anticancer Res. 2000, 20, 1041-1048 and references cited therein.
22. (a) For a review on the antiviral, cytotoxic, and antiprotozoal activities, see: Holý, A. Curr. Pharm. Des. 2003, 9, 2567-2592.
23. (b) For articles on antibacterial and antiparasitic activities, see: Srivastav, N. C.; Manning, T.; Kunimoto, D. Y.; Kumar, R. Bioorg. Med. Chem. 2007, 15, 2045-2053.
24. (c) Nguyen, C.; Ruda, G. F.; Schipani, A.; Kasinathan, G.; Leal, I.; Musso-Buendia, A.; Kaiser, M.; Brun, R.; Ruiz-Pérez, L. M.; Sahlberg, B. L.; Johansson, N. G.; González-Pacanowska, D.; Gilbert, I. H. J. Med. Chem. 2006, 49, 4183-4195.
25. (d) Smeijsters, L. J.; Franssen, F. F.; Naesens, L.; de Vries, E.; Holý, A.; Balzarini, J.; de Clercq, E.; Overdulve, J. P. Int. J. Antimicrob. Agents 1999, 12, 53-61.
26. (a) For some recent articles on nucleoside analogues, see: Zhang, X.; Amer, A.; Fan, X.; Balzarini, J.; Neyts, J.; de Clercq, E.; Prichard, M.; Kern, E.; Torrence, P. F. Bioorg. Chem. 2007, 35, 221-232.
27. (b) Vejcik, S. M.; Horton, D. Carbohydr. Res. 2007, 342, 806-818.
28. (c) Tang, Y.; Muthyala, R.; Vince, R. Bioorg. Med. Chem. 2006, 14, 5866-5875.
29. (d) Krištafor, V.; Raić-Malić, S.; Cetina, M.; Kralj, M.; Šuman, L.; Pavelić, K.; Balzarini, J.; de Clercq, E.; Mintas, M. Bioorg. Med. Chem. 2006, 14, 8126-8138.
30. (e) d'A. Lucero, B.; Gomes, C. R. B.; de P. P. Frugulhetti, I. C.; Faro, L. V.; Alvarenga, L.; de Souza, M. C. B. V.; de Souza, T. M. L.; Ferreira, V. F. Bioorg. Med. Chem. Lett. 2006, 16, 1010-1013.
31. (f) Zhou, S.; Kern, E. R.; Gullen, E.; Cheng, Y. C.; Drach, J. C.; Tamiya, S.; Mitsuya, H.; Zemlicka, J. J. Med. Chem. 2006, 49, 6120-6128.
32. (g) Barral, K.; Balzarini, J.; Neyts, J.; de Clercq, E.; Hider, R. C.; Camplo, M. J. Med. Chem. 2006, 49, 43-50.
33. (h) Amblard, F.; Aucagne, V.; Guenot, P.; Schinazi, R. F.; Agrofoglio, L. A. Bioorg. Med. Chem. 2005, 13, 1239-1248.
34. (i) Janeba, Z.; Balzarini, J.; Andrei, G.; Snoeck, R.; de Clercq, E.; Robins, M. J. J. Med. Chem. 2005, 48, 4690-4696.
35. (j) Koszytkowska-Stawińska, M.; Sas, W. Tetrahedron Lett. 2004, 45, 5437-5440.
36. (k) Hernández, A. I.; Balzarini, J.; Rodríguez-Barrios, F.; San-Félix, A.; Karlsson, A.; Gago, F.; Camarasa, M. J.; Pérez-Pérez, M. J. Bioorg. Med. Chem. Lett. 2003, 13, 3027-3030 and references cited therein.
37. (a) For some recent articles on nucleotide analogues, see: Krečmerová, M.; Holý, A.; Pískala, A.; Masojídková, M.; Andrei, G.; Naesens, L.; Neyts, J.; Balzarini, J.; de Clercq, E.; Snoeck, R. J. Med. Chem. 2007, 50, 1069-1077.
38. (b) Choo, H.; Beadle, J. R.; Chong, Y.; Trahan, J.; Hostetler, K. Y. Bioorg. Med. Chem. 2007, 15, 1771-1779.
39. (c) Valiaeva, N.; Beadle, J. R.; Aldern, K. A.; Trahan, J.; Hostetler, K. Y. Antiviral Res. 2006, 72, 10-19.
40. (d) Horejsi, K.; Andrei, G.; de Clercq, E.; Snoeck, R.; Pohl, R.; Holy, A. Bioorg. Med. Chem. 2006, 14, 8057-8065.
41. (e) Beadle, J. R.; Wan, W. B.; Ciesla, S. L.; Keith, K. A.; Hartline, C.; Kern, E. R.; Hostetler, K. Y. J. Med. Chem. 2006, 49, 2010-2015.
42. (f) Barral, K.; Priet, S.; Sire, J.; Neyts, J.; Balzarini, J.; Canard, B.; Alvarez, K. J. Med. Chem. 2006, 49, 7799-7806.
43. (g) Sauerbrei, A.; Meier, C.; Meerbach, A.; Schiel, M.; Helbig, B.; Wutzier, P. Antiviral Res. 2005, 67, 147-154.
44. (a) Tietze, L. F.; Brasche, G.; Gericke, K. Domino reactions in Organic Synthesis; Wiley-VCH: Weinheim, Germany, 2006.
45. (b) Enders, D.; Grondal, C.; Hüttl, M. R. M. Angew. Chem., Int. Ed. 2007, 46, 1570-1581.
46. (c) Nicolaou, K. C.; Edmons, D. J.; Bulger, P. G. Angew. Chem., Int. Ed. 2006, 45, 7134-7186.
47. (d) Pellissier, H. Tetrahedron 2006, 62, 1619-1665 (Part A)
48. and Tetrahedron 2006, 62, 2143-2173 (Part B).
49. (e) Guo, H.-C.; Ma, J.-A. Angew. Chem., Int. Ed. 2006, 45, 354-366.
50. (f) Wasilke, J. C.; Obrey, S. J.; Baker, R. T.; Bazan, G. C. Chem. Rev. 2005, 105, 1001-1020.
51. (g) Ajamian, A.; Gleason, J. L. Angew. Chem., Int. Ed. 2004, 43, 3754-3760.
52. (h) Parsons, P. J.; Penkett, C. S.; Shell, A. J. Chem. Rev. 1996, 96, 195-206.
53. (i) Tietze, L. F. Chem. Rev. 1996, 96, 115-136 and references cited therein.
54. (a) Boto, A.; Hernández, D.; Hernandez, R. Org. Lett. 2007, 9, 1721-1724.
55. (b) Boto, A.; Hernández, R.; Suárez, E. Tetrahedron Lett. 2001, 42, 9176-9170.
56. (c) Francisco, C. G.; González, C.; Suárez, E.; J. Org. Chem. 1998, 63, 8092-8093.
57. (d) de Armas, P.; Francisco, C. G.; Suárez, E. Angew. Chem., Int. Ed. Engl. 1992, 31, 112-11 A.
58. (e) For a review on the modification of carbohydrates through radical chemistry, see: Hansen, S. G.; Skrydstrup, T. Top. Curr. Chem. 2006, 264, 135-162.
59. Duvold, T.; Francis, G. W.; Papaioannou, D. Tetrahedron Lett. 1995, 36, 3153-3156.
60. Kaskar, B.; Heise, G. L.; Michalak, R. S.; Vishnuvajjala, B. R. Synthesis 1990, 1031-1032.
61. Francisco, C. G.; González, C.; Suárez, E. J. Org. Chem. 1998, 63, 2099-2109.
62. Zhao, H.; Hans, S.; Cheng, Y.; Mootoo, D. R. J. Org. Chem. 2001, 66, 1761-1767.
63. (a) Angyal, S. J.; Pickles, V. A.; Ahluwalia, R. Carbohydr. Res. 1967, 3, 300-307.
64. (b) For previous steps, see: Ferroud, D.; Collard, J.; Klick, M.; Dupuis-Hamelin, C.; Mauvais, P.; Lassaigne, P.; Bonnefoy, A.; Musicki, B. Biorg. Med. Chem. Lett. 1999, 9, 2881-2886.
65. (c) Collins, P. M.; Travis, A. S. J. Chem. Soc., Perkin Trans. 1 1980, 779-786.
66. (d) Bedini, E.; Parrilli, M.; Unverzagt, C. Tetrahedron Lett. 2002, 43, 8879-8882.
67. For a related mechanistic proposal, see: Boto, A.; Hernández, R.; León, Y.; Murguía, J. R.; Rodríguez-Afonso, A. Eur. J. Org. Chem. 2005, 673-682.
68. (a) Vorbrüggen, H. Acta Biochem. Pol. 1996, 43, 25-36.
69. (b) Drew, M. G. B.; Gorsuch, S.; Gould, J. H. M.; Mann, J. J. Chem. Soc., Perkin Trans. 1 1999, 969-978.
70. Crystallographic data for the compounds studied in the solid state have also been deposited in the Cambridge Crystallographic Data Centre as nos. CCDC-645469 (29), CCDC-645470 (36), CCDC-645471 (37), and CCDC-645472 (45). These data can be obtained free of charge via www.ccdc.cam.ac.uk/conts/retrieving.html (or from the Cambridge Crystallographic Data Centre, 12, Union Road Cambridge CB21EZ, UK; fax (+44) 1223-336-033; e-mail deposit@ccdc.cam.ac.uk).
71. For examples of other type of dimeric acyclic nucleosides, see: Doláková, P.; Dracínsky, M.; Holý, A. Antiviral Res. 2007, 74, 109 (A72).
72. Trost, B. M. Angew. Chem., Int. Ed. Engl. 1995, 34, 259-281.
73. (a) Heightman, T. D.; Locatelli, M.; Vasella, A. Helv. Chim. Acta 1996, 79, 2190-2200.
74. (b) Flessner, T.; Wong, C.-H. Tetrahedron Lett. 2000, 41, 7805-7808.
75. The antiviral activity of compounds 24-58 is currently under study, and will be published in due time. Previously, their cytotoxic activity was tested with three tumour cell lines: MCF7 (breast), NCI-H460 (lung), and SF-268 (glioma), displaying little cytotoxicity, as needed for a selective antiviral compound.
76. (a) Area-Detector Absorption Correction. SADABS within SAINT+ package, v. 7.06, 1996, BRUKER-AXS Inc., 5465 East Cheryl Parkway, Madison, WI.
77. (b) Altomare, A.; Burla, M. C.; Camalli, M.; Cascarano, G. L.; Giacovazzo, C.; Guagliardi, A.; Moliterni, A. G. G.; Polidori, G.; Spagna, R. J. Appl. Crystallogr. 1999, 32, 115-119.
78. (c) Program for Structure Solution, Refinement and Presentation, BRUKER-AXS Inc., 5465 East Cheryl Parkway, Madison, WI.
79. (d) Flack, H. D. Acta Crystallogr. 1983, A39, 876-881.